Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | SOD1 | P00441 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12075473 | 1.00 | MAPK1 (0.48) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL29686538 | 0.84 | SMN1; SMN2 (0.52) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL12075476 | 0.84 | SMN1; SMN2 (0.52) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL12075867 | 0.84 | SMN1; SMN2 (0.52) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL6159061 | 0.84 | SMN1; SMN2 (0.52) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL20201962 | 0.83 | ALDH1A1 (0.49) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL17277505 | 0.83 | SCN4A (0.50) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL17277359 | 0.83 | SCN4A (0.50) | MAPK1L3MBTL1TSHRTDP1KDM4E | |
| SCHEMBL17277545 | 0.81 | CFD (0.40) | — | |
| SCHEMBL17277322 | 0.81 | ADRB2 (0.52) | L3MBTL1SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | MAPK1 3970/4885L3MBTL1 606/4885TSHR 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.